The clean safety profile and novel mechanism validation are significant for Celldex's mast cell franchise. Watch for initiation of Phase 1b asthma data and subsequent proof-of-concept readouts in allergic rhinitis/food allergy, which could further de-risk the platform. The stock's 91% analyst bullish consensus and prior strong positive T+20 alpha on long calls suggest the market may reward this data.
Price Chart
Executive Summary
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug showed rapid, durable, dose-dependent reductions in serum tryptase (indicating mast cell depletion) and was well-tolerated at all doses with no dose-limiting toxicities or related serious adverse events. This validates a novel mechanism (neutralizing soluble SCF to selectively inhibit KIT signaling in mast cells) and supports advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy.
Key Facts
- CDX-622 induced rapid, profound, dose-dependent, and durable reductions in serum tryptase, indicating tissue mast cell depletion.
- No dose-limiting toxicities or related serious adverse events; most common adverse event was Grade 1 headache.
- No changes in hair/skin pigmentation or meaningful impact on hematologic parameters, addressing a key safety concern for KIT-targeting therapies.
- CDX-622 exhibited monoclonal antibody-like pharmacokinetics with extended half-life and good subcutaneous bioavailability.
- Phase 1b proof-of-mechanism study in mild to moderate asthma is ongoing; additional proof-of-concept studies in allergic rhinitis and food allergy are planned.
- Celldex also presented non-human primate data showing targeting soluble SCF depletes mast cells without affecting spermatogenesis or melanogenesis.
- CDX-622 builds on Celldex's barzolvolimab platform, which is in Phase 3 for chronic urticaria and Phase 2 for prurigo nodularis and atopic dermatitis.
Financial Impact
No financial data provided; clinical-stage biotech with no approved products or revenue. Positive Phase 1 data de-risks the CDX-622 program and expands Celldex's pipeline optionality in inflammatory diseases.
Risk Factors
- CDX-622 is still in early-stage development (Phase 1b); clinical failure in later-stage trials remains a risk.
- Competition from other mast cell-targeting therapies (e.g., barzolvolimab, other anti-SCF/TSLP agents) could limit commercial potential.
- No financial data or guidance provided; the company's cash runway and ability to fund multiple Phase 2 programs is not disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $31.65 (+1.46%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $31.65 (−1.46%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.65 (+5.64%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.65 (+5.64%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.65 (−6.83%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.65 (−6.83%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $31.65 (+0.89%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.65 (+1.90%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.65 (+1.90%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.65 (+1.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access